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Biophysics, School of Medicine, Bahcesehir University, Istanbul, TurkeyABSTRACT PDEd is a small protein that binds and controls the trafficking of RAS subfamily proteins. Its inhibition protects
initiation of RAS signaling, and it is one of the common targets considered for oncological drug development. In this study,
we used solved x-ray structures of inhibitor-bound PDEd targets to investigate mechanisms of action of six independent all-
atom MD simulations. An analysis of atomic simulations combined with the molecular mechanic-Poisson-Boltzmann solvent
accessible surface area/generalized Born solvent accessible surface area calculations led to the identification of action mech-
anisms for a panel of novel PDEd inhibitors. To the best of our knowledge, this study is one of the first in silico investigations on
co-crystallized PDEd protein. A detailed atomic-scale understanding of the molecular mechanism of PDEd inhibition may assist
in the design of novel PDEd inhibitors. One of the most common side effects for diverse small molecules/kinase inhibitors is their
off-target interactions with cardiac ion channels and human-ether-a-go-go channel specifically. Thus, all of the studied PDEd
inhibitors are also screened in silico at the central cavities of hERG1 potassium channels.INTRODUCTIONRAS (rat sarcoma) superfamily members belong to the
protein family of small GTPases. RAS regulates signaling
networks and cell proliferation (1). Abnormal cell signaling,
proliferation, and mutation of proto-oncogenes are known to
occur in cancer cells (2,3). RAS mutations are involved in
~30% of all human cancers, rendering this oncogene as
one of the major targets in anticancer drug development
(4). The three well-defined subfamilies of RAS proteins
are Harvey rat sarcoma viral oncogene homolog (H-RAS),
Kirsten rat sarcoma 2 viral oncogene homolog (K-RAS),
and neuroblastoma RAS viral oncogene homolog
(N-RAS) (5,6). RAS proteins are composed of 189 amino
acid residues with the first 85 amino acids strictly conserved
among family members (7). In the mostly observed human
cancer types, such as colon, lung, and pancreatic, mutations
of RAS genes have been observed (8). The K-RAS consists
of two isoforms: K-RAS4A, which exists in the viral K-RAS
oncogene and 4B preferably denoted in human cells (9,10);
and K-RAS4B, which is the most important isoform of
the RAS proteins, and which hold a central position in the
transduction of growth-promoting signals across the plasma
membrane to regulate cell growth and differentiation.
Signaling activity of K-RAS is dependent on its enrichment
level in the plasma membrane (PM). Moreover, PM speci-
ficity is related to the electrostatic interactions between
PM and K-RAS (3). Recently, PM localization of RAS pro-Submitted February 20, 2015, and accepted for publication August 3, 2015.
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0006-3495/15/09/1163/6teins is thought to be dependent on the PDEd activity levels
(7). Additionally, PDEd regulates RAS activity and may
suppress oncogenic RAS-related signaling in cells. Conse-
quently, interfering with K-RAS signaling is significant to
obtain useful anticancer drugs. In recent studies, several
benzimidazole compounds have been found to be good
inhibitors of the KRAS-PDEd communication (11). These
small molecules bind selectively to the binding pocket of
PDEd to inhibit oncogenic signaling of K-RAS. This inhibi-
tion suppresses cancer cell proliferation and tumor growth.MATERIALS AND METHODS
Protein preparation process
In this study, co-crystallized PDEd complexes were retrieved from Protein
Data Bank (PDB ID: 4JV6, 4JV8, 4JVB, 4JVF) (11) and their coordinates
were used as the initial inputs for independent molecular dynamics (MD)
simulations. Missing amino acid residues at the crystal structures were
identified and predictively modeled using implemented MODELER
9.12 code (12) in UCSF Chimera (13) based on the amino acid sequence
of PDEd that was retrieved from the UniProt Knowledgebase
(UniProtKB) server (14) (ID: O43924). Missing hydrogen atoms were
then added, and the protonation properties of the proteins were assigned
in the physiological pH (pH: 7.4) by utilizing the implemented PROPKA
module (15) in the protein preparation wizard of the Maestro molecular
modeling package (16). Finally all atoms of the systems were submitted
in restrained molecular mechanics (MM) minimizations by employing the
OPLS2005 force field. Complexes (PDB ID: 4JV6 and 4JV8) contain li-
gands 1 and S1 in two domains of the binding pocket, respectively. These
binding sites are identified by Tyr149 and Arg61 amino acid residues as
critical key residues in each domain. Systems were constructed for each
complex individually, with six systems in total elucidated (detailed in
Results and Discussion).http://dx.doi.org/10.1016/j.bpj.2015.08.001
1164 Salmas et al.MD simulations
In our study two MD simulation programs (NAMD and AMBER) were
used for different postprocessing analyses.
NAMD simulations
Before independent MD simulations, each structure was solvated with
TIP3P water molecules using 15 A˚ solvent layers around the protein com-
plexes surface, and simulations were performed with NAMD 2.9 code (17)
(see Fig. S1 in the Supporting Material).
The neutralizing counterions were added to represent physiological con-
centration of 0.15 M KCl. The CHARMM 36 and CHARMM general force
field (CgenFF) (18,19) force fields were used to represent the protein-ligand
systems. Heavy atom bond lengths with hydrogen atoms and the internal
geometry of water molecules were fixed using the SHAKE algorithm.
The simulations were run under periodic boundary conditions (PBC) with
a 12 A˚ cut-off for nonbonding interactions. The particle mesh Ewald
(PME) method was used to treat long-range electrostatic interactions.
Before starting the MD production run, a two-equilibration stage was
used: 1) the protein-ligand atoms were fixed, and the water molecules
were allowed to relax for 1 ns and 2) all atoms were relaxed with a 1 ns
equilibration run. Finally, 70 ns MD simulations (as production run) at
constant pressure (1 atm) and temperature (300 K) were performed at the
canonical ensemble for each systems. For all MD simulations, a time
step of 2 fs was used. Trajectory frames were generated for every 10 ps
for a total of 70 ns. All of the MD frames were analyzed using the modules
with the VMD program package (20).
AMBER simulations
To apply Poisson-Boltzmann (PB) solvent accessible surface area/general-
ized Born (GB) solvent accessible surface area (PBSA/GBSA) methods,
independent MD simulations were individually performed for each of the
complexes. Constructed and repaired systems (see the protein preparation
section) were incorporated in these MD simulations. AMBER 12 code
(21) was used for all classical MD simulations. The AMBER ff99SB force
field (22) was utilized for atomic partial charges and bond, angle, dihedral,
and van der Waals parameters were used for all atoms of proteins.
Parameter data of proteins were constructed using the tLEaP module of
AMBERTOOLS 13. The ANTECHAMBER module was employed to
use the Gasteiger atomic partial charges individually for each of the inhib-
itors, and the general AMBER GAFF force field (23) was used to prepare
the force field parameters. The systems were neutralized in tLEaP with
Naþ counterions and solvated with the explicit solvation method that is rep-
resented by TIP3P water model. Long-range electrostatic interactions were
calculated using the PME method. All of the systems were simulated at the
temperature of 300 K and the pressure of 1 atm for total of 50 ns production
run. A time step of 2 fs was used for all MD simulations. Minimization and
equilibration processes were then carried out to derive initial coordination
for each studied system.Nonbonding interaction energy estimations
To understand the role of individual amino acids in the active sites of PDEd
complexes, each complex was submitted in nonbonding interaction energy
calculations. To accomplish this, all amino acid residues within 6 A˚ from
ligand were considered and their nonbonding energy values between ligand
and amino acid residues were calculated using the NAMD energy plugin in
VMD (20). Interaction energy values were estimated as follows:





These calculations were carried out using all generated MD trajectory
frames and the average values of estimated interaction energy were consid-
ered. The implicit solvation method was employed for MM calculations.Biophysical Journal 109(6) 1163–1168MM-PBSA/GBSA binding free energy calculations
Binding free-energy predictions have proven to be useful methods for many
subjects in molecular modeling studies of biology systems, such as protein-
ligand interactions, drug screening, and drug discovery (24). MM-PBSA/
GBSA is a modern method that calculates the binding free energies of
the complex (protein þ ligand) systems based on MD simulations (24).
The free energy of binding can be described as a composition of enthalpy
and entropy as follows:
DGbind ¼ DH  TDS (2)
DH in Eq. 2 can be shown as follows:
DH ¼ DEMM þ DGsol; (3)
where DEMM describes the molecular mechanics interaction energy be-
tween the receptor and the inhibitor, and DGsol is the solvation free energy.
DEMM is expressed as follows (4):
DEMM ¼ DEelec þ DEvdW ; (4)
where each of the DEelec and DEvdW defines electrostatic interaction energy
and van der Waals interaction energy, respectively. DGsol is further divided
as follows:
DGsol ¼ DGPB=GB þ DGNP; (5)
where DGPB/GB defines the polar solvation energy calculated by PB and GB
methods using the PBSA module of AMBER 12. DGNP describes nonpolar
solvation energy that is predicted through estimation of the solvent-acces-
sible surface area (SASA) as follows:
DGNP ¼ gSASAþ b; (6)
where the surface tension (g) and the offset (b) was set the standard values
of 0.005420 kcal mol1 A˚2 and 1.008000 kcal mol1, respectively.
DGNP was estimated with the linear combinations of the pairwise overlaps
(LCPO) method (25). In SASA calculation, a probe radius of 1.4 A˚was as-
signed for the solvent. MMPBSA.py is a program written in Python and
nab. In this study, both the PB and GB methods were considered for the
calculation of binding free energies. MMPBSA.py, Python, and the nab-
scripted program of AMBER 12 was utilized to perform these energetic cal-
culations. One thousand trajectory frames from 50 ns MD simulations were
submitted for each of the postprocessing binding free-energy calculations.Docking simulations
PDEd inhibitors, as with many other anticancer drugs, display various side
effects related to off-target interactions with cardiac channels, and most
notably with the hERG1 channel (26). The Glide/XP (extra precision) dock-
ing method (27) was used to estimate the binding energy values between the
inhibitors and hERG1 channels. Predicted open active and open-inactive
hERG1 models from our earlier study (28) were used as receptor targets.
Docking grids were identified for both models by utilizing the positions
of Tyr652, Phe565, Ser649, Thr623, and Ser624 amino acid residues, and
then all inhibitors were docked into the active sites of hERG1 channel
models.RESULTS AND DISCUSSION
The x-ray structures provided an in-depth view of the po-
tential organization of the binding pocket and key ligating
Action Mechanisms of PDEd Inhibitors 1165properties of the site. However, the receptor flexibility al-
lowing specificity in ligand recognition often is a critical
factor in the protein-ligand association. Therefore, there
is an apparent need to understand conformational ensem-
bles responsible for high affinity and high specificity of
the receptor binding sites. One of the most popular ap-
proaches for this kind of problem is MD simulations.
MD allows generation of the ensemble of structures
that can be used for accurate computations of thermody-
namics potentials such as binding free energies. The aim
of this study was to investigate the binding mechanisms
responsible for high-affinity binding for reported PDEd in-
hibitors (11). In our study six independent MD simulations
were performed. All initial PDEd coordinate files were
retrieved from available x-ray crystal structures, which
were solved by Zimmermann et al. (11). These x-ray struc-
tures show co-crystallized ligands bound to the active site
(Fig. 1).
PDEd has a large binding pocket, which has mainly two
essential regions. Compounds 2 and 5 have extensive
structures and can be localized in these two regions. How-
ever, compounds 1 and S1 have relatively small sizes and
can be localized in either the first or second regions. (In
our study, we called these regions 1 and 2 at the binding
pocket, which are near the Tyr149 and Arg61 key amino
acid residues, respectively). To check the structural
effects of the inhibitors 1 and S1 in both regions, we per-
formed MD simulations in the two regions individually
for these inhibitors. To illustrate the most likely pose of
the inhibitors from the ensemble generated by MD simu-
lations in a single snapshot, the average structures were
calculated and used for root mean-square deviation
(RMSD) fitting. The frame with the coordinates closest
to the average structure (i.e., RMSD values are calculated
in respect to the average conformer for each frame)
was selected as a representative snapshot from whole
7000 frames, which are derived from 70 ns MD
simulations.FIGURE 1 Chemical structures of novel inhibitors (co-crystallized) used
in this study.Fig. 2 shows the representative structures of ligands 2
and 5 during MD simulations. Their coordinates at the
active site are superimposed with coordinates of the co-
crystallized ligands. Distinct poses are not observed be-
tween the co-crystallized and representative ligands from
MD simulations in the PDEd active site for both ligands.
This indicates a high stability of the inhibitors at the bind-
ing pocket.
Two-dimensional ligand interaction diagrams are profiled
for compounds 2 and 5, which show interactions of com-
pounds within 4 A˚ distance threshold (see Fig. S2). As
Fig. S2 clearly shows, Arg61 and Tyr149 established
H-bonding interactions with compounds 2 and 5. Also
strong p-p stacking interactions are formed with Trp32
for both ligands. These extended ligands cover overall bind-
ing pocket of the PDEd as shown in Fig. 2.Hydrogen bond occupancy analysis and
per-residue interaction energy estimations
To understand the H-bonding population of each inhibitor
during simulation with key amino acid residues of the
PDEd, H-bond analysis were performed independently for
each inhibitor. The percentage of H-bond occupancy during
simulations was calculated for studied six different systems
and plotted in Fig. 3.
These profile shows valuable information of the
H-bonding network during inhibitory treatment. The inhib-
itor 5 constructs a diverse H-bonding network at the binding
pocket with several key amino acids such as Tyr149, Arg61,
Val145, Met118, and Leu38. This may explain inhibitor 5’s
strong inhibitory profile (10 nM). Ligand 1 in two different
active site positions (i.e., 11 and 12) formed different
H-bonding interactions. PDEd involves a single extended
binding cavity at the x-ray structure that includes both
Arg61 and Tyr149 amino acids. Compounds 1 and S1 at re-
gion 1 (11 and S11) formed H-bonds with Tyr149 with the
occupancy of 28% and 75%, respectively. These inhibitors
at region 2 (12 and S12) constructed H-bonds mainly with
Arg61 with the occupancy of 50.45% and 56.55%, respec-
tively. Moreover, per-residue interaction energy analysis
were obtained between individual amino acid residues-
inhibitor interactions as shown in Fig. 4.
Arg61 was indicated as a key residue for ligand interac-
tion for all inhibitors except ligands 11 and S11, as expected.Binding enthalpies from the MM-PBSA/GBSA
computations
To estimate binding free energies of the four different inhib-
itors with PDEd, both MM-PBSA and MM-GBSA methods
were used. The analysis of binding thermodynamics for the
six complexes is shown in Table 1. The free-energy decom-
position to individual components illustrates the impact
of each energy contribution to the binding affinity of theBiophysical Journal 109(6) 1163–1168
FIGURE 2 Structural superposition of crystal-
lized PDEd enzyme (green) with equilibrated
K-RAS via MD simulations (red). Interacted with
ligands 2 (a) and 5 (b).
1166 Salmas et al.receptor to various ligands. In all complex formations, the
computed binding enthalpies overestimate the experimental
results. Nevertheless, the binding enthalpies are positively
correlated with the measured affinities.
Table 1 includes results of binding enthalpy estimations
using MM-PBSA/GBSA calculations for all studied sys-
tems. The experimental binding affinity values of bound li-
gands toward PDEd reported by Zimmermann et al. (11)
and their converted DG values are also listed in the Table 1.
Parallel to the experimental results, MM-PBSA/GBSA
analysis showed that inhibitor 5 has the most strongly
bounded ligand at the active site (Table 1). The compound
2 has the second-highest inhibitory activity based on our
predictions and experimental results. For compounds 1
and S1, energetic estimations of the four complex forma-
tions were individually examined. As described in Mate-
rials and Methods, these ligands are small in size;
therefore, the two independent ligand-binding pockets of
the receptor were studied and also the average binding
energy of both pockets were accurately considered. The
ligand 1 revealed an absolute higher binding free energy
compared with ligand S1 in the first binding pocket of
the PDEd. However, the ligand S1 displayed higher pre-
dicted affinity to the second binding site. The binding
enthalpy differences between the first and second binding
pockets were calculated for ligand 1 and ligand S1
(Table 1). Both inhibitors have theoretically shared the
similar binding energy values. There was no significant
difference between the binding energies of both ligands ac-
cording experimental results (DGexp of ligands 1 and S1
are 9.30 and 8.02 kcal/mole, respectively). In additionFIGURE 3 The occupancy of the hydrogen bond between protein and li-
gands.
Biophysical Journal 109(6) 1163–1168to the free-energy differences, other individual energy
components were also derived, such as van der Waals, elec-
trostatic, polar solvation, nonpolar solvation, and MM
interaction energies. These results illustrate that van der
Waals and electrostatic interaction energies are treated
favorably by the binding sites of all complexes. Particu-
larly, these energy components within the PDEd in com-
plex with inhibitors 2 and 5 are amply pronounced,
because of the fact that ligands 2 and 5 are more extended
in size in comparison with other inhibitors (1 and S1).Stability and clustering analysis
Conformational clustering analyses were also performed for
the studied inhibitors during MD simulations. Fig. 5 clearly
illustrates the evolution of the conformational transitions
for each inhibitor in various positions in the course of MD
simulations.
RMSD calculations of heavy atoms were carried out on
the six ligands to examine the conformational stability of
the inhibitor in the active site of PDEd during the simulation
(Fig. S3). Ligand 11 was more unstable compared with
the other inhibitors throughout the simulation. Inhibitor
5 fluctuated less than other compounds as expected. To un-
derstand the influence of each inhibitor to overall PDEd
structure, root-mean-square fluctuation (RMSF) calcula-
tions were also applied (Fig. 6).
The average flexibility of individual amino acid residues
in respect to the six ligands bound was plotted. The lowest
amino acids fluctuations were found for inhibitors 5 and 2.FIGURE 4 The nonbonded interaction energy analysis between residues
in the active site and ligands.
TABLE 1 Energetic analysis for PDEd complexes as obtained by MM-GBSA/PBSA calculations
Energy
(kcal/mole) 11 12 11 and 12 S11 S12 S11 and S12 2 5
DEvdw 41.885 2.10 38.875 2.36 40.37 38.965 2.14 41.825 2.34 40.39 79.515 3.43 76.195 3.37
DEelec 3.575 1.21 4.465 2.36 4.01 3.555 1.87 4.375 1.63 3.96 84.635 13.06 11.895 1.71
DEMM 45.455 2.47 43.345 2.72 44.39 42.515 2.83 46.195 3.17 44.35 164.155 13.64 88.095 3.75
DGp (gb) 10.825 1.30 10.715 1.52 10.76 12.835 1.96 10.575 1.36 11.7 102.055 12.03 22.905 1.49
DGnp (gb) 5.255 0.17 5.355 0.22 5.30 4.955 0.20 5.445 0.18 5.19 10.395 0.30 10.195 0.28
DGsolv 5.575 1.32 5.365 1.55 5.36 7.875 1.90 5.125 1.29 6.49 91.665 12.02 12.715 1.49
DGelec(tot)
a 7.25 6.25 6.75 9.28 6.2 7.74 17.42 11.01
DGMM-GBSA 39.895 2.16 37.995 2.30 38.94 34.655 2.33 41.075 2.63 37.86 72.505 4.02 75.395 3.77
DGMM-PBSA 32.375 2.41 29.725 2.56 31.04 29.485 2.82 32.765 2.75 31.2 58.665 4.45 59.255 3.74
KD exp (nM) 1655 23 1655 23 14205 480 14205 480 395 11 105 3
DGexp 9.30 8.02 10.16 10.97
50 ns MD simulations were carried out for all the systems using AMBER.
aDGelec (tot) ¼ DGelec þ DGp (gb).
Action Mechanisms of PDEd Inhibitors 1167The less-stable protein structure during simulation was
found for ligand 11.Cardiotoxicity
One of the most common side effects reported for a number
of diverse small molecules is their off-target interactions
with cardiac ion channels especially with hERG K channels.
Thus, all of these novel, to our knowledge, PDEd inhibitors
were also screened in silico at the central cavities of model
hERG1 channels using our previously developed hERG1
open and open-inactivated S1–S6 TM domains (28). In the
derivation of these channel models, available experimental
constraints were used (29-31). All six novel inhibitors
were docked into the active site of two models of hERG1,
and the calculated docking score values are listed in
Table S1.
Three-dimensional and two-dimensional docking poses
of ligands 1 and 2 are displayed in Figs. S4 and S5, respec-
tively. Our simulations results show that all novel inhibitors
have high docking scores at open inactivated hERG1models. Therefore, our molecular simulations suggest that
rehabilitation of these inhibitors is needed before further
biological tests can be undertaken.CONCLUSIONS
In summary, we have performed six long-range indepen-
dent classic MD simulations. To investigate the mechanistic
inhibitory treatment of PDEd bound to novel various inhib-
itors, different postprocessing MD analyses were carried
out. In this article, we reported on the capacity of each in-
hibitor to cover the active site of PDEd protein and also on
the stability of inhibitors by means of RMSD, RMSF, and
clustering analysis approaches at the binding site. In addi-
tion, we also carried out binding enthalpy estimation
studies of ligands. To the best of our knowledge, this study
is one of the first in silico investigation of the PDEd pro-
tein. A detailed atomic scale understanding of molecular
mechanism of PDEd inhibition may assist in the design
and development of novel and more potent PDEd
inhibitors.FIGURE 5 Illustrative structures of the studied
ligand conformations in PDEd protein using clus-
tering analysis.
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FIGURE 6 The root-mean-square fluctuation (RMSF) values calculated
from the 70 ns MD trajectories for all inhibitor complexed with PDEd pro-
tein are displayed versus the residue number.
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